This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IOBT IO Biotech (IOBT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipTrendsBuy This Stock About IO Biotech Stock (NASDAQ:IOBT) Get IO Biotech alerts:Sign Up Key Stats Today's Range$0.05▼$0.0550-Day Range$0.03▼$0.2152-Week Range$0.03▼$2.79VolumeN/AAverage Volume7.09 million shsMarket Capitalization$3.45 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingReduce Company Overview IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors. Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma. The company’s pipeline also explores combination regimens that pair its vaccine technology with established checkpoint inhibitors to enhance therapeutic efficacy. Research and development activities are conducted in Denmark, with ongoing collaborations and trial sites across Europe and North America to support global patient access. IO Biotech is led by an experienced management team with deep expertise in immunology, oncology drug development and regulatory affairs. The company’s strategic focus remains on translating its innate immune-priming technology into differentiated cancer treatments and expanding its clinical footprint through partnerships and investigator-initiated studies.AI Generated. May Contain Errors. Read More Receive IOBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IOBT Stock News HeadlinesIO Biotech: After Considering All Strategic Alternatives, Co. Ceased Operations and Filed aVoluntary Petition for Relief Under Provisions of Chapter 7 of Title 11 of U.S ...March 31, 2026 | marketwatch.comWhy Are Shares Of IO Biotech Plummeting?March 31, 2026 | benzinga.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.July 6 at 1:00 AM | Reagan Gold Group (Ad)IO Biotech (IOBT) price target decreased by 33.83% to 1.66February 4, 2026 | msn.comIO Biotech Engages Raymond James as Financial Advisor Amid Workforce Reduction and Cost-Containment MeasuresJanuary 30, 2026 | quiverquant.comQIO Biotech Provides Corporate UpdateJanuary 30, 2026 | globenewswire.comPiper Sandler downgrades IO Biotech (IOBT)January 27, 2026 | msn.comPiper downgrades IO Biotech amid strategic alternatives evaluationJanuary 27, 2026 | finance.yahoo.comSee More Headlines IOBT Stock Analysis - Frequently Asked Questions How were IO Biotech's earnings last quarter? IO Biotech, Inc. (NASDAQ:IOBT) issued its quarterly earnings results on Friday, November, 14th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. When did IO Biotech IPO? IO Biotech (IOBT) raised $111 million in an IPO on Thursday, November 4th 2021. The company issued 7,150,000 shares at $14.00-$17.00 per share. What other stocks do shareholders of IO Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that IO Biotech investors own include Compass Pathways (CMPS), Nkarta (NKTX), PayPal (PYPL), AbCellera Biologics (ABCL), Atai Beckley (ATAI), Meta Platforms (META) and Company Calendar Last Earnings11/14/2025Today7/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 IOBT's financial health is in the Red zone, according to TradeSmith. IOBT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IOBT CIK1865494 Webwww.iobiotech.com Phone45-7070-2980FaxN/AEmployees30Year Founded2014Price Target and Rating Average Price Target for IO Biotech$3.50 High Price Target$4.00 Low Price Target$3.00 Potential Upside/Downside+7,191.7%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$95.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-517.22% Return on Assets-200.69% Debt Debt-to-Equity Ratio18.29 Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.07Miscellaneous Outstanding Shares71,949,000Free Float68,495,000Market Cap$3.45 million OptionableNot Optionable Beta0.88 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:IOBT) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersThree companies about to leapfrog Nvidia [And transform the entire industry]The government just committed $200 billion to building computer chips on American soil - one of the largest te...Eagle Publishing | SponsoredAmazon, Google, Meta, and Microsoft just committed $700 billionAmazon, Google, Meta, and Microsoft have committed $700 billion this year alone to AI infrastructure - more th...True Market Insiders | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IO Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOBT Stock Alerts